Thomas Stankovich - Nov 30, 2023 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
Chief Financial Officer
Signature
/s/ Thomas Stankovich
Stock symbol
RSLS
Transactions as of
Nov 30, 2023
Transactions value $
-$39
Form type
4
Date filed
8/13/2024, 04:29 PM
Previous filing
Nov 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock, $0.001 par value per share Sale -$9 -39 -0.17% $0.23 22.9K Nov 30, 2023 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale -$11 -42 -0.18% $0.25 22.9K Dec 31, 2023 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale -$7 -43 -0.19% $0.17 22.8K Feb 29, 2024 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale -$12 -48 -0.21% $0.25 22.8K May 31, 2024 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.